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Abstract
In Duchenne muscular dystrophy (DMD) little has been reported on the association between clinical outcome measures and patient health-
related quality of life (HRQOL) tools. Our study evaluated the relationship between 12 month changes on the Generic Core Scales (GCS), the
Multidimensional Fatigue Scale and the Neuromuscular Module of the PedsQLTM with several outcome measures (6 minute walk test, North Star
Ambulatory Assessment and timed items) in ambulatory DMD. Ninety-eight ambulatory DMD in a multicentric setting were included in the study.
At baseline, the PedsQLTM inventories correlated with almost all the functional measures On the Child Self-Report there was a significant decrease
between baseline and 12 months on the PedsQLTM GCS and its first domain, in parallel with the decrement in the functional outcome measures.
Correlation between the 12 month changes on the PedsQLTM inventories and functional measures were almost all negligible. Similar results were
obtained on the Parent Proxy-Report.
In conclusion, PedsQLTM correlates with the level of impairment at baseline, but this does not hold true when 12 month changes are considered.
Further studies comparing different tools are needed to better elucidate the complexity of the relationship between HRQOL and functional
performances.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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1. Introduction
In the last few years promising new therapies for Duchenne
muscular dystrophy (DMD), including nonsense mutation
suppression via stop codon read through and exon skipping via
antisense oligonucleotides, have been introduced into registration-
directed international multicentre investigational drug clinical
trials. Safety and efficacy trials have involved both ambulatory and
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nonambulatory subgroups of DMD populations [1–6], even
though most of the recent and ongoing studies focus on the
ambulatory phase [7–9]. The 6 minute walk test (6MWT) has been
recently chosen as the primary outcome measure in both
international multicentre investigational drug clinical trials and
longitudinal natural history studies in DMD ambulant patients
[7–13]. It provides an integrated global assessment of ambulatory
function that is influenced by decreased lower extremity strength,
biomechanical inefficiencies during gait, diminished endurance,
and compromised cardio-respiratory status [14]. Functional scales,
such as the North Star Ambulatory Assessment (NSAA), represent
an ideal additional tool to the 6MWT, as they provide information
on a wider spectrum of functions that reflect everyday life activities
[15]. We have recently reported data from multicentric longitudinal
studies in ambulant DMD boys, describing the changes on both
6MWT and NSAA and providing cut-off values to predict the risk
of losing ambulation within 12, 24 and 36 months [10–12].
There has been an increasing pressure from regulatory
authorities to include health-related quality of life (HRQOL)
assessments in order to test the impact of possible functional
changes on activities of daily living and more generally,
on patient’s quality of life. The Paediatric Quality of Life
Inventory with its Generic Core Scales (PedsQLTM GCS) is the
most used tool to assess quality of life in clinical studies and a
specific module for neuromuscular disorders, the PedsQLTM
Neuromuscular Model (PedsQLTM NMM), has been validated
in DMD and spinal muscular atrophy (SMA) [16,17].
The PedsQLTM Multidimensional Fatigue Scale (PedsQLTM
MFS) was designed as a child self-report and parent proxy-report
generic symptom-specific instrument to measure fatigue in
pediatric patients [18] and has never been used in neuromuscular
disorders.
A few studies have recently reported the use of these
modules in DMD cohorts [19–21], but little has been reported
on if and how the PedsQLTM scores change in relation to
longitudinal changes on the functional measures commonly
used in therapeutic trials and clinical practice, such as the
6MWT and NSAA [21].
The aim of our study was to assess if 12 month changes in
function, assessed by 6MWT, NSAA, 10 meter timed walk/run
and Gowers test, were associated to changes on HRQOL tools
in a large cohort of ambulant DMD boys. In order to assess
possible differences among the most commonly used HRQOL
tools we used the PedsQLTM GCS, the PedsQLTM MFS and the
PedsQLTM NMM, both in the Child Self-Report and Parent
Proxy-Report.
2. Subjects and methods
The study is a prospective longitudinal multicentric cohort
study involving patients recruited from 10 tertiary neuromuscular
centers in Italy and followed for at least one year.
Patient inclusion criteria were:
(i) genetically proven DMD diagnosis, aged between 5 and
13 years. The age of 5 as lower limit was chosen as both
6MWT and NSAA have been validated from this age and
the upper limit of 13 years as we wished to select a
population similar to that included in most of the current
clinical trials in DMD.
(ii) still ambulant and able to walk independently for at least
75 meters, and
(iii) without severe or moderate learning difficulties or
behavioral problems, that could affect compliance or the
level of performance.
All consecutive patients attending the 10 participating centers
who fulfilled the inclusion criteria were enrolled in the study. As
part of this study, all centers performed the NSAA followed by
the 6MWT at each visit. As we wished to obtain the best
compliance in the functional assessments also in younger
patients, the PedsQLTM modules were filled in after the functional
tasks at variance with the administration guideline suggestions. A
research assistant assisted the younger children (5–7 years) in
completing the questionnaires and was available to assist the
older group if needed. Data were collected at baseline and at
12-month follow-up assessment.
This study is part of a longer longitudinal study on 6MWT
and NSAA in DMD involving the same centers [10–12,22,23].
Details of the training for the participants and of the
interobserver reliability for measures among the centers have
already been reported in our previous studies [22,23].
2.1. Standard protocol approvals, registrations and patient
consents
The study was approved by the ethical committee of each
center. Written informed consent was obtained from participants.
2.1.1. PedsQLTM
In order to assess the suitability of the different PedsQLTM
modules in DMD, we used the Italian version not only of the
general module (PedsQLTM GCS), but also of the dedicated
module for neuromuscular disorders (PedsQLTM NMM) and of
the PedsQLTM Multidimensional Fatigue Scale (MFS). We also
separately analyzed the results of the first domain of each
module (respectively: Physical Function Score, General Fatigue
Scale, About My Neuromuscular Disease), as they are supposed
to be more related to patient functional status [20].
The PedsQLTM is a modular instrument designed to measure
HRQOL in children and adolescents aged 2–18 years. The
23 − item PedsQLTM 4.0 GCS encompasses: (1) Physical
Functioning (8 items), (2) Emotional Functioning (5 items), (3)
Social Functioning (5 items) and (4) School Functioning (5
items). The 18-item PedsQLTM MFS was designed to measure
fatigue in pediatric patients and comprises the General Fatigue
Scale (6 items), Sleep/Rest Fatigue Scale (6 items), and
Cognitive Fatigue Scale (6 items). The 25-item PedsQLTM 3.0
NMM encompasses 3 Scales: (1) About My/My Child’s
Neuromuscular Disease (17 items), (2) Communication (3
items) and 3) About Our Family Resources (5 items). The
PedsQLTM NMM young child form (5–7 years) does not contain
the Communication and About Our Family Resources Scales.
All three inventories include parallel Child Self-Report and
Parent Proxy-Report formats for children aged 5–18 years. The
versions for patients between 5 and 7 years have 3-choice
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answers, the other versions have 5 choices answers. The
instructions, Likert response scale, and scoring method for the
PedsQLTM modules are identical. For each item the score can
vary between 0 and 4. Items are linearly transformed to a 0 to
100 scale (0 = 100, 1 = 75, 2 = 50, 3 = 25 and 4 = 0), with
higher scores indicating better HRQOL.
2.1.2. 6MWT
6MWT was performed in all DMD ambulant boys older than
5 years using a modified version of the American Thoracic
Society guidelines for the test [24]. Modifications include the
addition of continuous encouragement from the testing staff,
and a “safety chaser” to walk along behind the subject during
testing. The test is generally completed within 15–20 minutes.
Suitability and interrater and intrarater reliability in DMD for
the 6MWT have already been reported [14,23,25].
2.1.3. NSAA
The scale consists of 17 items, ranging from standing (item
1) to running (item 17) and includes several items assessing
abilities that are necessary to remain functionally ambulant.
Each item can be scored on a 3 point scale using simple criteria:
2 – Normal, achieves goal without any assistance; 1 – Modified
method, but achieves goal independent of physical assistance
from another person; 0 – Unable to achieve independently. The
score can range from 0, if all the activities are failed, to 34, if all
the activities are achieved. The scale is generally completed in
a maximum of 15 minutes.
2.1.4. Timed items
The NSAA also includes the possibility to record timed
items (10 meter timed walk/run test and time to rise from the
floor or Gowers test) [22]. The time taken to complete these
tasks is not part of the score, but provides an additional measure
that can be monitored over time. In children who were or
became unable to perform these tasks, conventionally a time
equal to the worst performance in the group was subjectively
given to indicate poor performance [10]. Reliability of the
NSAA and timed items in the same multicentric setting has
already been tested with positive results [22].
2.1.5. Statistical analysis
Continuous variables are presented as mean ± standard
deviation (SD) and categorical variables as frequencies and
percentages. Paired t-tests were used for comparisons of the
measures across time (baseline and 12 months). Delta of the
measure evaluations were calculated as the difference between 12
month and baseline data. The relation between the PedsQLTM and
functional data was assessed by bivariate correlations (Pearson’s
correlations). All hypothesis tests conducted were 2-tailed. A p
value < 0.05 was considered statistically significant. Statistical
analyses were performed using SAS (SAS version [9.2] of the
SAS System. Copyright © 2002–2008 by SAS Institute Inc.,
Cary, NC, USA).
3. Results
One hundred and seven patients fulfilled the inclusion
criteria and participated in the study, but 9 patients were lost at
follow-up. Ninety-eight patients (mean age = 8.4 years, SD
2.29) had both baseline and follow-up data and were included in
the analysis. Forty-three patients were aged 7 years or below.
Within the year when the study was performed, 9 of the 98
patients lost the ability to complete the 6MWT and timed items
and were included in the analysis with a result equal to the worst
performance in the group. All the tests were performed safely
without any major fall during the assessments.
3.1. Baseline data
Descriptive statistics for PedsQLTM Child Self-Report,
Parent Proxy-Report and functional data at baseline are shown
in Tables 1 and 2.
Table 1
Descriptive statistics for PedsQLTM Child Self-Report and Parent Proxy-Report data at baseline and at 12 month follow-up. Mean (±SD).
Children Parents
Baseline 12 months p Baseline 12 months p
PedsQLTM Generic Core Scales (GSC) 74.5 (±15.8) 71.5 (±16.3) *0.04 68.3 (±14.2) 64.6 (±15.8) ***0.0008
PedsQLTM GSC – 1° domain (Physical Function Score) 68.9 (±21.9) 64.4 (±21.1) *0.03 61.5 (±19.0) 58.5 (±20.8) 0.09
PedsQLTM Multidimensional Fatigue Scale (PedsQL MFS) 76.3 (±17.4) 76.3 (±15.2) 0.89 79.0 (±13.2) 74.2 (±17.5) **0.002
PedsQLTM MFS – 1° domain (General Fatigue Scale) 75.9 (±21.1) 73.7 (±18.5) 0.29 71.6 (±18.7) 66.8 (±19.1) **0.005
PedsQLTM Neuromuscular Module (NMM) 81.4 (±12.8) 81.2 (±13.3) 0.77 75.8 (±15.6) 71.3 (±16.6) ***0.0005
PedsQLTM NMM – 1° domain (About My Neuromuscular Disease) 82.3 (±10.7) 81.2 (±13.2) 0.77 81.4 (±12.3) 78.5 (±12.9) **0.005
p significant values in bold. *p < 0.05, **p < 0.01, ***p < 0.001 or above.
Table 2
6 minute walk test (6MWT), North Star Ambulatory Assessment (NSAA), 10 meter timed walk/run test (10 meter) and Gowers test data at baseline, at 12 month
follow-up and changes over 12 months (Delta). Mean (±SD, range).
Baseline 12 Months DELTA p
6MWT (m) 383.8 (±88.9, 119.5–546.2) 345.5 (±139.8, 0–563) −38.3 (±82.6, −285–184.5) ***<0.0001
North Star Ambulatory Assessment Score (34/34) 24.2 (±6.8, 4–34) 21.6 (±9.1, 0–34) −2.6 (±4.7, −14.7–12) ***<0.0001
10 meter timed walk/run test (s) 7.4 (±2.6, 3.6–17.4) 8.9 (±5.4, 2–24) 1.5 (±3.8, −5.4–14.9) ***0.0009
Gowers test (s) 8.0 (±6.8, 1.41–27) 11.8 (±10.7, 2–31) 3.8 (±6.2, −3.6–29.6) ***<0.0001
p significant values in bold. *p < 0.05, **p < 0.01, ***p < 0.001 or above.
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3.2. Correlations between PedsQLTM and functional data at
baseline
3.2.1. PedsQLTM child self−report
At baseline the PedsQLTM GCS and the GCS-first domain,
The GSC-Physical Function Score, correlated with age and all
the functional measures with the strongest correlation found
with Gowers test. The PedsQLTM MFS correlated with Gowers
test and 6MWT and its first domain, the MFS-General Fatigue
Scale, with 6MWT only. The PedsQLTM NMM correlated with
all the functional measures with the exception of NSAA and its
first domain, PedsQLTM NMM-About My Neuromuscular
Disorder, did not show any significant correlation. All the other
correlations were not significant. Details in Table 3.
3.2.2. PedsQLTM parent proxy-report
At baseline the PedsQLTM GCS and the GCS-first domain
correlated with age and all the functional measures with the
strongest correlations found between GCS-Physical Function
Score and NSAA, Gowers test and 6MWT.
Both the PedsQLTM MFS and the MFS-first domain correlated
with 6MWT.
The PedsQLTM NMM correlated with 10 meter and 6MWT and
its first domain, the PedsQLTM NMM-About My Neuromuscular
Disease, correlated with all outcome measures, with the strongest
correlation with 6MWT. All the other correlations were not
significant. Details in Table 3.
3.3. Longitudinal data
On the Child Self-Report scores there was a significant
decrease between baseline and 12 months in the PedsQLTM
GCS and its first domain (GSC-Physical Function Score). All
the other inventories did not significantly differ between
baseline and 12 months (Table 1).
On the Parent Proxy-Report there was a significant decrease
between baseline and 12 months on all tools with the exception
of the GCS – Physical Function Score (Table 1).
All the selected functional outcome measures detected a
significant decline in function over the 12-month period
(Table 2). The decline was more obvious in the subgroup of boys
above the age of 7 years (p < 0.001), as the younger ones did not
shown a significant difference over the 12-month period, with
several patients showing an improvement in all the selected
outcome measures. Significant correlations were found between
baseline values and the 12-month changes of functional scales
[10].
3.4. Correlation of 12 month changes
3.4.1. PedsQLTM child self-report
The correlation between the 12 month changes on the
PedsQLTM GCS and the other PedsQLTM tools were all significant
with the strongest correlation with its first domain (PedsQLTM
GCS-Physical Function Score) r = 0.64, p = < 0.0001.
Table 3
Correlations between PedsQLTM Child Self- and Parent Proxy-Report and age and functional measures at baseline.
Age NSAA 10 meters Gowers test 6MWT
Baseline child self-report
PedsQLTM Generic Core Scales (GSC) r = −0.33
**p < 0.001
r = 0.26
*p = 0.01
r = −0.26
**p = 0.009
r = −0.43
***p < 0.0001
r = 0.27
**p = 0.008
PedsQLTM GSC – 1° domain (PFS) r = −0.36
***p = 0.0004
r = 0.32
**p = 0.002
r = −0.34
***p = 0.0007
r = −0.41
***p < 0.0001
r = 0.25
*p = 0.02
PedsQLTM Multidimensional Fatigue Scale (PedsQLTM MFS) r = −0.04
p = 0.68
r = 0.20
p = 0.06
r = −0.18
p = 0.09
r = −0.21
**p = 0.04
r = 0.23
*p = 0.02
PedsQLTM MFS – 1° domain (GFS) r = 0.11
p = 0.31
r = 0.14
p = 0.17
r = −0.16
p = 0.13
r = −0.17
*p = 0.1
r = 0.26
*p = 0.01
PedsQLTM NM r = −0.10
p = 0.30
r = 0.18
p = 0.07
r = −0.24
*p = 0.02
r = −0.26
*p < 0.01
r = 0.20
*p = 0.04
PedsQLTM NM – 1° domain r = −0.02
p = 0.88
r = 0.15
p = 0.14
r = −0.16
p = 0.12
r = −0.18
p = 0.08
r = 0.13
p = 0.22
Baseline parent proxy-report
PedsQL Generic Core Scales (GSC) r = −0.34
***p = 0.0007
r = 0.36
***p = 0.0004
r = −0.31
**p = 0.002
r = −0.36
***p = 0.0002
r = 0.36
***p = 0.0003
PedsQL GSC – 1° domain (PFS) r = −0.30
**p = 0.003
r = 0.43
***p < 0.0001
r = −0.39
***p < 0.0001
r = −0.45
***p < 0.0001
r = 0.49
***p < 0.0001
PedsQL Multidimensional Fatigue Scale (PedsQL MFS) r = −0.03
p = 0.77
r = 0.18
p = 0.08
r = −0.16
p = 0.13
r = −0.12
p = 0.25
r = 0.27
**p = 0.006
PedsQL MFS – 1° domain (GFS) r = −0.02
p = 0.9
r = 0.16
p = 0.12
r = −0.16
p = 0.13
r=−0.14
p = 0.18
r = 0.26
**p = 0.009
PedsQL NM r = −0.05
p = 0.6
r = 0.15
p = 0.13
r = −0.25
*p = 0.01
r = −0.15
p = 0.15
r = 0.21
*p = 0.04
PedsQL NM – 1° domain r = −0.17
p = 0.1
r = 0.38
***p = 0.0001
r = −0.35
***p = 0.0004
r = −0.29
**p = 0.0001
r = 0.46
***p < 0.0001
p significant values in bold. * p <0.05, **p < 0.01, ***p < 0.001 or above.
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The correlation between the 12 month changes on the
PedsQLTM inventories and the functional measures were all
negligible with the exceptions of the PedsQLTM MFS with 10
meter timed walk/run test and PedsQLTM NMM-About My
Neuromuscular Disease and Gowers test.
A correlation with age was shown for some of the
inventories (Table 4). Fig. 1 shows as example the distribution
of individual changes on PedsQLTM GCS and functional scales.
When we considered the subgroup of patients above the age of
7, the correlation between the 12 month changes on the
PedsQLTM inventories and the functional measures were also all
negligible with the exceptions of the 12 month changes on
PedsQLTM MFS and 6MWT (r = 0.24, p = 0.01). In this
subgroup, a correlation with age was shown for some of the
inventories (PedsQLTM NMM, r = 0.27, p = 0.004; PedsQLTM
NMM-About My Neuromuscular Disease, r = 0.36, p = 0.0001).
3.4.2. PedsQLTM parent proxy-report
The correlation between the 12 month changes on the
PedsQLTM GCS and the other PedsQLTM tools were all significant
with the strongest correlation with its first domain: vs PedsQLTM
GCS-Physical Function Score, r = 0.64, p = < 0.0001.
The correlation between the 12 month changes on the
PedsQLTM inventories and the functional measures were all
negligible with the exceptions of PedsQLTM GCS-Physical
Function Score and NSAA and the MFS-General Fatigue Scale
and age, 10 meter timed walk/run test and 6MWT. A correlation
with age was shown only for the PedsQLTM NMM (Table 4).
When we considered the subgroup of patients above the age
of 7, the correlation between the 12 month changes on the
PedsQLTM inventories and the functional measures were also all
negligible with the exceptions of the 12 month changes on
PedsQLTM GCS-Physical Function Score and Gowers test
(r = 0.23, p = 0.01) and between PedsQLTM MFS and 6MWT
(r = 0.25, p = 0.01).
A correlation with age was shown for some of the inventories
(PedsQLTM MFS-General Fatigue Scale, r = 0.23, p = 0.01,
PedsQLTM NMM, r = 0.28, p = 0.003; PedsQLTM NMM-About
My Neuromuscular Disease, r = 0.38, p = 0.0001).
4. Discussion
The use of relatively new functional outcome measures in
clinical trials in boys with DMD has highlighted the need to better
understand how changes in these measures relate to quality of life.
In the last few years there has therefore been increasing interest to
identify HRQOL tools to be included as a secondary outcome
measures in clinical trials in children with DMD. Although
HRQOL measurements have been increasingly acknowledged as
essential health outcome measures in clinical trials, the available
pediatric tools are very scanty and the choice is even poorer if we
look for disease-specific measures. Generic pediatric HRQOL
instruments have been widely used in several disorders. They have
the advantage that they enable comparisons across pediatric
populations and facilitate benchmarking with healthy population
norms. Disease-specific measures on the other hand have the
advantage of enhancing measurement sensitivity for health
domains germane to a particular chronic health condition. The
PedsQLTM is a versatile instrument widely used in children with
chronic diseases [26]. Several disease-specific modules have also
Table 4
Correlations of delta outcome measures.
Age NSAA 10 meters Gowers test 6MWT
Delta child self-report
PedsQLTM Generic Core Scales (GSC) r = −0.10
p = 0.33
r = −0.03
p = 0.75
r = −0.13
p = 0.22
r = −0.04
p = 0.72
r = 0.06
p = 0.58
PedsQLTM GSC – 1° domain (Physical Function Score) r = −0.01
p = 0.89
r = 0.09
p = 0.37
r = −0.17
p = 0.11
r = −0.03
p = 0.75
r = −0.03
p = 0.81
PedsQLTM Multidimensional Fatigue Scale (PedsQLTM MFS) r = −0.15
p = 0.15
r = 0.02
p = 0.83
r = −0.22
*p = 0.03
r = −0.09
p = 0.38
r = 0.002
p = 0.98
PedsQLTM MFS – 1° domain (General Fatigue Scale) r = −0.31
**p = 0.003
r = 0.03
p = 0.75
r = 0.05
p = 0.63
r = 0.02
p = 0.86
r = 0.09
p = 0.38
PedsQLTM Neuromuscular Module (NM) r = −0.21
*p = 0.04
r = 0.03
p = 0.75
r = −0.07
p = 0.47
r = −0.18
p = 0.08
r = 0.02
p = 0.87
PedsQLTM NM – 1° domain (About My Neuromuscular Disease) r = −0.35
***p = 0.0005
r = 0.09
p = 0.37
r = −0.14
p = 0.18
r = −0.22
*p = 0.03
r = 0.05
p = 0.64
Delta parent proxy-report
PedsQL Generic Core Scales (GSC) r = −0.08
p = 0.44
r = 0.03
p = 0.77
r = −0.11
p = 0.31
r = −0.02
p = 0.82
r = 0.05
p = 0.65
PedsQL GSC – 1° domain (Physical Function Score) r = −0.15
p = 0.15
r = 0.22
*p = 0.03
r = −0.19
p = 0.06
r = −0.13
p = 0.1
r = 0.19
p = 0.057
PedsQL Multidimensional Fatigue Scale (PedsQL MFS) r = −0.07
p = 0.49
r=−0.03
p = 0.74
r = −0.09
p = 0.38
r = −0.05
p = 0.64
r = −0.01
p = 0.93
PedsQL MFS – 1° domain (General Fatigue Scale) r = −0.24
*p = 0.02
r = 0.14
p = 0.18
r = −0.21
*p = 0.04
r = −0.1
p = 0.34
r = 0.26
*p = 0.01
PedsQL Neuromuscular Module (NM) r = −0.23
*p = 0.02
r = 0.02
p = 0.87
r = −0.05
p = 0.85
r = 0.08
p = 0.43
r = 0.07
p = 0.5
PedsQL NM – 1° domain (About My Neuromuscular Disease) r = −0.14
p = 0.16
r = 0.02
p = 0.082
r = −0.04
p = 0.69
r = −0.006
p = 0.95
r = 0.09
p = 0.37
p significant values in bold. *p < 0.05, **p < 0.01, ***p < 0.001 or above.
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been developed, such as those for asthma, arthritis, cancer,
cardiac disease, diabetes. The recent PedsQLTM NMM, originally
developed for children with SMA [17], was subsequently also
applied in DMD boys, also in comparison with an other DMD
version [16,19]. In this study we used both the generic PedsQLTM
GCS and the dedicated neuromuscular module. Furthermore, as
fatigability is an important issue in DMD boys and is partly
recorded by the 6MWT, we also decided to use the fatigability
scale, the PedsQLTM MFS. We focused on their global scores and
on the first domains, supposed to better relate to functional aspects,
this resulting in a choice of 6 measures of HRQOL.
Our results showed that the total scores of PedsQLTM GCS
Child Self-Report were between 25.78 and 100 at baseline and
between 38.81 and 100 at 12 months with an average of 74.5
and 71 respectively. The average scores in our cohort are lower
than those reported for healthy controls in two previous studies
(between 87 and 88.8) [16,19], but higher than in their DMD
cohorts, as these ranged between 60.4 and 62.7 [16,19]. The
results however are not easily comparable because of different
inclusion criteria as we included only ambulant boys from the
age of 5 and in the first of the two previous studies [16] nearly
90% of the DMD boys were non ambulant and the second
focused on the 8–12 years age range [19].
Another difference with previous studies is that by also
including younger boys, we were able to compare parents’ and
children’s responses in all ambulatory age range. With one
exception parents’ responses were always lower than children’s
self report both at baseline and at 12 months. These findings
confirm and expand previous evidence of poor agreement
between parents’ and children’s responses [16,19].
The aim of our study however was not to duplicate previous
reports on quality of life in DMD or their correlation with
different demographic data or intervention such as steroids, but
to establish the value of the questionnaires in assessing changes
in HRQOL in relation to possible functional changes. Our
results showed that at baseline all the inventories used showed
correlations with the functional status. The PedsQLTM GCS, both
as a global scale and the first domain specifically addressing
physical function scores (PedsQLTM GCS – PFS), showed a
significant correlation with all the functional measures both on
children’s and parents’ versions. The PedsQLTM MFS had an
overall weaker correlation than the PedsQLTM GCS and in the
parents’ questionnaires the correlation was limited to the 6MWT.
At variance with previous studies [19–21], we also used the
PedsQLTM NMM, a module specifically devised for patients
with NMD and validated in DMD, with selected items thought
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Fig. 1. Distribution of individual 12 month changes of PedsQLTM Child Self-Report Generic Core Scales scores versus 6MWT (A), NSAA (B), 10 meter timed
walk/run test (10 meter) (C) and Gowers test (D) according to age (≤ or >7 years).
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to be more relevant for the disease [16]. Surprisingly, its use did
not appear to increase the level of significance compared to the
general module with the exception of the first domain, that
better correlated with all functional measures in the parents’
questionnaire.
It is of interest that the 6MWT appeared to be the measure
that at baseline better correlated with all the inventories.
When we assessed the possible concordance of 12 month
changes between PedsQLTM GCS versus its first domain
PedsQLTM GCS – PFS and the other PedsQLTM measures, we
found significant correlations with the strongest correlation
with its first domain in both parents’ and children’s versions.
In contrast, the correlation was often not significant between
the 12 month changes on the different PedsQLTM tools and
the functional assessments. While the functional scores
significantly decreased over 12 months, the results of the
inventories were more variable. On the Child Self-Report
scores, only the GCS and its first domain PedsQLTM GCS – PFS
had a significant decrement over 12 months. At variance, on the
parents’ version the scores decreased with age and disease
progression as previously reported by other studies [19–21]
with the exception of the PedsQLTM GCS – PFS, although this
tool is targeted to functional aspects. Even when the mean
changes observed on the functional tests and on the inventories
were concordant, trending in the same direction, the changes in
the two groups of tools did not always happen in the same
direction in individual patients (e.g. in Fig. 1). As a result, the
overall correlation between changes in function and PedsQL TM
was, with few exceptions, not significant both in the whole
cohort and in the subset of patients above the age of 7 years.
Interestingly, in the subset of patients above the age of 7 years
we found a correlation between changes in PedsQLTM MFS
and 6MWT both on children’s and parents’ versions. This is
not surprising considering that the 6MWT is a measure of
endurance and may better reflect fatigability, as also shown in
the correlation between PedsQLTM MFS parents’ version and
6MWT at baseline.
The only previous longitudinal study reporting both
PedsQLTM parental self-report and functional measures changes
in 24 DMD boys with age range similar to our cohort showed a
weak correlation at baseline between PedsQLTM GCS and
6MWT and timed items. Thirteen of the 24 also had follow-up
assessments and the correlation of the 12 month changes was
negligible [21]. Our study, performed in a larger cohort and
using additional measures, confirm that 12 month changes in
functional measures may not always be reflected on PedsQLTM
scores in both children’s and parents’ versions. Both studies
suggest that the PedsQLTM may not be appropriate to mirror the
functional changes observed as part of the natural history in
DMD, at least in ambulant patients and in the age range
included in the two studies (4–12 and 5–13 years).
This is an important point as the PedsQLTM has already been
chosen as a secondary or exploratory outcome measure in many
recent and ongoing trials following the need of regulators,
families and researchers to add additional measures that would
support the clinical meaningfulness of the 6MWT or other
primary outcome measures.
In conclusion, our results suggest that the PedsQLTM
correlates with the level of impairment in DMD boys between
the age of 5 and 13 years, but this does not hold true when 12
month changes are considered. This might be explained by the
construct of the questionnaires including, for example in the
PedsQLTM NMM module, a number of questions regarding
difficulties in breathing, frequency in illness, communication or
family resources, that are unlikely to change in parallel with
functional performances, particularly at this disease stage and
over 12 months.
Previous studies using other tools, such as the Pediatric
Outcomes Data Collection Instrument (PODCI), have shown
higher sensitivity to functional changes over 12 months in
ambulant DMD compared to PedsQLTM [21]. This difference
may be explained by the fact that the PODCI response options
address the perceived physical difficulty of activities: e.g.
“during the last week has it been easy or hard for your child to
walk one block?”, response options include :“easy, a little hard,
very hard, can’t do at all”. In contrast, the PedsQLTM response
in based on self-selected frequency and/or importance: e.g. “In
the past one month how much of a problem has your child had
with. . .”, response choices include “never, almost never,
sometimes, often and almost always”.
Our findings highlight the complexity of the relationship
between HRQOL tools and functional measures. Functional
changes on the 6MWT and on the NSAA reflect changes on
activities of daily living, that are not always addressed by
PedsQLTM and other available HRQOL tools. Furthermore,
PedsQLTM scores reflect also social and emotional aspects that
may not parallel to functional changes.
Further studies on longer time frame or using other tools,
such as the PODCI and/or specific questionnaires addressing
changes in activity of daily living, may help to elucidate to
which extend the available pediatric HRQOL tools are capable
of mirroring the functional changes and/or eventually to
identify new valuable tools.
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